Critical Review: Interventional Neuroradiology Journal

Publisher & Frequency: Published by SAGE (Centauro SRL, Italy) in association with the World Federation of Interventional and Therapeutic Neuroradiology. Bimonthly since 1995.
Impact Factor & Ranking:
- Clarivate Impact Factor (2021): ~1.76
- Scopus CiteScore (2023): ~1.59
- Scimago SJR (2023): 0.543 (Q2)
- h-index: ~44

These metrics place INR in the mid-tier (Q2) among neuroradiology journals.

Focused Scope: Excels at case reports, novel techniques, and translational studies in interventional neuroradiology.
International Editorial Board: Members from Mayo Clinic, Oxford, Tokyo, etc.
Ethical Standards: Member of COPE (Committee on Publication Ethics).

Modest Citation Impact: Lower than top-tier journals such as JNIS or *Neuroradiology*.
Few High-Level Trials: Mostly observational studies; rare randomized controlled trials.
Quality Variability: Some studies with limited statistical or methodological robustness.

Compared to journals like:

INR has less international prestige. Landmark clinical trials often appear in general medical journals like NEJM, Lancet, or JAMA.

Feature	Strength	Limitation
Specialty Focus	High	Narrow scope
Peer Review & Ethics	COPE membership	Some technical/statistical issues
Clinical Trials	Accepts early-stage innovations	RCTs often published elsewhere
Prestige	Q2	Lower visibility vs top neuro journals

Overall: A respected, specialized journal ideal for technique-oriented studies, early innovation, and practical interventional insights.

Authors: Ideal for pilot data, case series, and technical reports. For large-scale trials, consider higher-impact venues.
Readers: Useful for staying current with procedural advances. Supplement with broader-evidence journals for guidelines and trials.